FDA Refuses To Review Moderna's mRNA Flu Vaccine Application
FDA issued a refusal-to-file for Moderna's mRNA-1010, citing an inadequate comparator in the 40,700-person Phase 3 trial.
Scientific AmericanFDA won’t consider a new mRNA vaccine for flu despite the technology’s life-saving promise
Boston GlobeModerna says FDA refuses its application for new mRNA flu vaccine
Joe.My.God.FDA Refuses To Review Moderna's First mRNA Flu Vax
ARS TechnicaFDA refuses to review Moderna’s mRNA flu vaccine
Overview
The U.S. Food and Drug Administration issued a refusal-to-file letter for Moderna's mRNA-1010 flu vaccine on Feb. 3, citing that the Phase 3 comparator 'does not reflect the best-available standard of care,' according to a letter signed by Dr. Vinay Prasad.
The refusal follows a 40,700-person trial that Moderna said showed mRNA-1010 was about 26.6% more effective than Fluarix in adults 50 and older, and Moderna said the FDA accepted its trial design in April 2024 and August 2025.
Moderna CEO Stéphane Bancel said the Centers for Biologics Evaluation and Research raised no safety or efficacy concerns and the company requested an urgent meeting, while HHS spokesperson Andrew Nixon said the FDA generally does not comment on communications to sponsors.
The decision comes after Health Secretary Robert F. Kennedy Jr. canceled about $500 million in mRNA research funding and amid FDA moves to tighten vaccine approval standards, a shift that European, Canadian and Australian regulators have not mirrored for mRNA-1010, Moderna said.
Moderna paused U.S. review of a combined flu-COVID mRNA shot and said it expects likely first approval in Europe this year, and the company plans to press the FDA for reconsideration and additional discussions.
Analysis
Center-leaning sources frame the story as regulatory politicization: they emphasize FDA hostility under Health Secretary Robert F. Kennedy Jr., use evaluative terms (e.g., “fervent anti‑vaccine activist,” “slow‑walking”), prioritize Moderna’s rebuttals and safety data, and foreground policy actions and funding cuts—editorial choices that suggest a narrative of politicized scrutiny rather than neutral procedural disagreement.
FAQ
The FDA cited that the Phase 3 trial's comparator, a standard-dose flu vaccine like Fluarix, did not reflect the best-available standard of care.